It is especially relevant for patients with overweight or obesity who also have high blood pressure, high cholesterol, elevated blood sugar, insulin resistance, fatty liver risk, sleep apnea, a family history of heart disease, or prior cardiovascular disease
Clinical trials have demonstrated weight loss ranging from approximately 10% with GLP-1 agents at weight management doses (e.g., semaglutide 2.4 mg in the STEP trials) to over 20% with tirzepatide at higher doses (SURMOUNT trials)
A TSH Test and thyroid hormones may be checked for ordinary thyroid-function concerns, but they do not screen for medullary thyroid carcinoma
But she said the drugs curate an environment that allow behavioral changes to take hold
doi: 10.1001/jama.2021.1831 103 CowartK